← Human Trials & Peer-Reviewed Studies
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
Plain-language guide to PMID 41138739 (2025): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 41138739
- Journal
- Lancet (London, England)
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Deanfield J et al. (21 authors)
- DOI
- 10.1016/S0140-6736(25)01375-3
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
The researchers report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
In this analysis, risk of MACE occurring after 20 weeks was assessed between patients by adiposity changes in the first 20 weeks and, in a separate analysis, all in-trial MACE were assessed between patients by adiposity changes over 104 weeks.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.
Some participants received a placebo instead of Semaglutide, giving a reference point.
A time span of 20 weeks appears in the methods.
Adiposity measures included weight and waist circumference.
This trial is registered with ClinicalTrials.gov, NCT03574597.
What Was Measured
The researchers report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk.
PubMed files the paper under topics including Adiposity, Body Mass Index, Cardiovascular Diseases, Obesity, Overweight, Waist Circumference and Glucagon-Like Peptide-1 Receptor Agonists.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide over 20 weeks.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (Lancet (London, England)), a journal based in England.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.